Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
| Dublin Core | PKP Metadata Items | Metadata for this Document | |
| 1. | Title | Title of document | Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia |
| 2. | Creator | Author's name, affiliation, country | Vera A Gorbunova; N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation |
| 2. | Creator | Author's name, affiliation, country | Irina V Kolyadina; N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation |
| 2. | Creator | Author's name, affiliation, country | Elena I Kovalenko; N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation |
| 2. | Creator | Author's name, affiliation, country | Liudmila V Manziuk; N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation |
| 2. | Creator | Author's name, affiliation, country | Elena V Artamonova; N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation |
| 2. | Creator | Author's name, affiliation, country | Liudmila G Zhukova; A.S.Loginov Moscow Clinical Scientific Practical Center of the Department of Health of Moscow |
| 2. | Creator | Author's name, affiliation, country | Larisa V Bolotina; P.A.Herzen Moscow Research Institute of Oncology - branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation |
| 2. | Creator | Author's name, affiliation, country | Tat'iana Iu Semiglazova; N.N.Petrov National Medical Research Center of Oncology |
| 2. | Creator | Author's name, affiliation, country | Aleksei G Manikhas; City Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Natal'ia A Raevskaia; City Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Il'ia M Itkin; City Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Dmitrii V Filonenko; Moscow City Oncology Hospital №62 of the Department of Health of Moscow |
| 2. | Creator | Author's name, affiliation, country | Larisa A Zhilyaeva; Kursk Regional Clinical Oncology Center |
| 2. | Creator | Author's name, affiliation, country | Viktor E Gol'dberg; Research Institute of Oncology of the Tomsk National Research Medical Center of the Russian Academy of Sciences |
| 2. | Creator | Author's name, affiliation, country | Natal'ia O Popova; Research Institute of Oncology of the Tomsk National Research Medical Center of the Russian Academy of Sciences |
| 2. | Creator | Author's name, affiliation, country | Dmitrii M Ponomarenko; Regional Oncology Center |
| 2. | Creator | Author's name, affiliation, country | Valentina E Shikina; Moscow Regional Oncological Dispensary |
| 2. | Creator | Author's name, affiliation, country | Irina R Suslova; Oncologic Dispensary №4 |
| 2. | Creator | Author's name, affiliation, country | Olga V Romanchuk; Oncologic Dispensary №4 |
| 2. | Creator | Author's name, affiliation, country | Dmitrii V Kozlov; Diagnostic Clinical Center №1 |
| 2. | Creator | Author's name, affiliation, country | Ali-Dzarakhmat S Rzaev; Diagnostic Clinical Center №1 |
| 2. | Creator | Author's name, affiliation, country | Vasilii V Marfutov; A.S.Loginov Moscow Clinical Scientific Practical Center |
| 2. | Creator | Author's name, affiliation, country | Irina I Andreiashkina; A.S.Loginov Moscow Clinical Scientific Practical Center |
| 2. | Creator | Author's name, affiliation, country | Liubov' I Vladimirova; Rostov Research Institute of Oncology |
| 2. | Creator | Author's name, affiliation, country | Irina S Mitashok; Rostov Research Institute of Oncology |
| 2. | Creator | Author's name, affiliation, country | Natal'ia M Tikhanovskaia; Rostov Research Institute of Oncology |
| 2. | Creator | Author's name, affiliation, country | Elena V Karabina; Tula Regional Oncologic Dispensary |
| 2. | Creator | Author's name, affiliation, country | Guzel' Z Mukhametshina; Republican Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Al'fiia I Khasanova; Republican Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Sufiia Z Safina; Republican Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Mikhail V Shaidorov; N.N.Blokhin National Medical Research Center of Oncology |
| 2. | Creator | Author's name, affiliation, country | Dmitrii A Morozov; N.N.Blokhin National Medical Research Center of Oncology |
| 2. | Creator | Author's name, affiliation, country | Elena P Prokof'eva; Penza Regional Oncology Center |
| 2. | Creator | Author's name, affiliation, country | Liudmila V Kramskaia; D.D.Pletnev City Clinical Hospital, a separate division "Oncological Dispensary" |
| 2. | Creator | Author's name, affiliation, country | Tat'iana V Karandeeva; D.D.Pletnev City Clinical Hospital, a separate division "Oncological Dispensary" |
| 2. | Creator | Author's name, affiliation, country | Irina V Evstigneeva; Tver Regional Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Elena G Ovchinnikova; Nizhny Novgorod Regional Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Tat'iana P Klement'eva; Nizhny Novgorod Regional Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Olga V Khrupalo; Diagnostic Clinical Center №1 |
| 2. | Creator | Author's name, affiliation, country | Elena V Tiuvinova; City Polyclinic №201 |
| 2. | Creator | Author's name, affiliation, country | Viktor M Sherstnev; Oncologic Dispensary №5 |
| 2. | Creator | Author's name, affiliation, country | Igor' S Chernov; Oncologic Dispensary №5 |
| 2. | Creator | Author's name, affiliation, country | Dzheims Dzh Kolokolov; City Polyclinic №195 |
| 2. | Creator | Author's name, affiliation, country | Elena A Gaisina; "Medical City" |
| 2. | Creator | Author's name, affiliation, country | Natal'ia V Levchenko; Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care |
| 2. | Creator | Author's name, affiliation, country | Viacheslav A Chubenko; Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care |
| 2. | Creator | Author's name, affiliation, country | Anton Iu Povyshev; District Clinical Hospital |
| 2. | Creator | Author's name, affiliation, country | Inna V Iudina; Clinical Oncologic Dispensary |
| 2. | Creator | Author's name, affiliation, country | Liudmila V Vorotilina; Clinical Oncologic Dispensary |
| 2. | Creator | Author's name, affiliation, country | Tat'iana V Andreeva; Smolensk Regional Oncological Dispensary |
| 2. | Creator | Author's name, affiliation, country | Garnik S Tumanian; Primorsky Regional Oncology Center |
| 2. | Creator | Author's name, affiliation, country | Anton E Koziakov; Novosibirsk Regional Clinical Oncologic Dispensary |
| 2. | Creator | Author's name, affiliation, country | Liudmila A Gil'mutdinova; Regional Clinical Center of Oncology |
| 2. | Creator | Author's name, affiliation, country | Mikhail A Osipov; Leningrad Regional Oncological Dispensary |
| 2. | Creator | Author's name, affiliation, country | Alina S Shatokhina; Clinical Oncology Dispensary №1 |
| 2. | Creator | Author's name, affiliation, country | Alena A Vazhenina; Medical Center "Sunrise Clinic" |
| 2. | Creator | Author's name, affiliation, country | Angelina S Chichkanova; Privolzhskii District Medical Center |
| 2. | Creator | Author's name, affiliation, country | Vladimir I Vladimirov; Pyatigorsk Interdistrict Oncologic Dispensary |
| 2. | Creator | Author's name, affiliation, country | Aleksandr N Ivanov; Republican Clinical Oncologic Dispensary |
| 2. | Creator | Author's name, affiliation, country | Anna S Belokhvostova; Republican Oncology Center |
| 2. | Creator | Author's name, affiliation, country | Elena M Cherniakova; Republican Oncology Center |
| 2. | Creator | Author's name, affiliation, country | Elena A Tul'china; Bryansk Regional Oncological Center |
| 2. | Creator | Author's name, affiliation, country | Svetlana A Maklashova; Bryansk Regional Oncological Center |
| 2. | Creator | Author's name, affiliation, country | Oksana N Shkodenko; Stavropol Regional Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Iuliia V Kostalanova; Samara Regional Clinical Oncology Dispensary |
| 2. | Creator | Author's name, affiliation, country | Anna V Tarasova; Tolyatti City Clinical Hospital №5 |
| 2. | Creator | Author's name, affiliation, country | Evgeniia S Kuz'mina; Salekhard District Clinical Hospital |
| 3. | Subject | Discipline(s) | |
| 3. | Subject | Keyword(s) | metastatic breast cancer; chemotherapy; eribulin; the Russian experience with eribulin |
| 4. | Description | Abstract | Aim. The aim of the study is to examine the efficacy and safety of eribulin in HER2-negative metastatic breast cancer (BC) in Russian clinical practice. Materials and methods. The analysis included 459 patients with advanced BC from 44 federal and municipal medical clinics in Russia and received at least 2 courses of treatment with eribulin in accordance with the registered indications for drug. The average age of women was 56 years (between 29 and 81 years), 83% of patients had HER2-negative tumor subtype (49.9% - luminal BC and 33.1% - triple-negative BC) HER2-positive biological tumor subtype was registered in 17% of patients. Visceral metastases were diagnosed in 73% of patients and three-zone and multiple zone metastases were diagnosed in 41.6% of cases. The median number of prior lines of therapy in patients with disseminated disease was 2; anthracycline and taxane chemotherapy was applied in 94.3% of patients, and 38.1% of patients were recived CT plus capecitabine. Standard treatment regimen with eribulin was cotinuing (1.4 mg/m² as a 2-5-minute intravenous infusion administrated on days 1, 8 of a 21-day cycle) until disease progression, unacceptable toxic effects, or impossibility of the drug administration for any other reason. We estimated the efficacy and safety of treatment with eribulin in Russian patients with HER2-negative BC. Results. Objective response rate was achieved in 20.5% of cases, complete response rate was in 3.2%, partial - 17.3%, and the stable disease rate was marked in 52.7% of women, and in 19.7% of these cases was prolonged more than 6 months. The frequency of objective response was higher in luminal BC group compared with triple-negative BC: 23.5% vs 15.8%; tumor growth control 76.9% vs. 67.8%, respectively; p<0.05. Median progression-free survival was 4.83 months (5.17 months - luminal BC and 4.0 months - triple-negative BC). On application of eribulin in first-, second- and third-line treatment we achived maximum efficiency: the frequency of objective response rate was 24.2%, tumor growth control - 82.2%, median progression-free survival - 5.07 months; any data were achived on drug application in fourth-line and further lines of treatment: 15.4%, 58.6% and 4.27 months, respectively; p<0.05. We showed the group of women with "special response" to eribulin (72 cases, 19%) associated with the high efficacy of therapy, regardless of biological subtypes and metastases localization: objective response rate - 48.6%, long-term stable disease rate - 51.4%. The safety profile of eribulin was acceptable; the dose reduction to 1.1 mg/m² was required only in 14.2% of patients and after the reduction eribulin therapy was continued without moderate adverse events. Conclusions. Efficacy and safety of eribulin therapy in Russian patients completely confirm the results of earlier randomized studies. The combination of efficiency in tumors with different biological subtypes and a safety profile makes eribulin the therapeutic option of appling in patients with advanced anthracycline-and taxan-resistant BC. |
| 5. | Publisher | Organizing agency, location | LLC Obyedinennaya Redaktsiya |
| 6. | Contributor | Sponsor(s) | |
| 7. | Date | (DD-MM-YYYY) | 15.03.2019 |
| 8. | Type | Status & genre | Peer-reviewed Article |
| 8. | Type | Type | Research Article |
| 9. | Format | File format | |
| 10. | Identifier | Uniform Resource Identifier | https://modernonco.orscience.ru/1815-1434/article/view/33502 |
| 10. | Identifier | Digital Object Identifier (DOI) | 10.26442/18151434.2019.1.190250 |
| 11. | Source | Title; vol., no. (year) | Journal of Modern Oncology; Vol 21, No 1 (2019) |
| 12. | Language | English=en | ru |
| 13. | Relation | Supp. Files | |
| 14. | Coverage | Geo-spatial location, chronological period, research sample (gender, age, etc.) | |
| 15. | Rights | Copyright and permissions |
Copyright (c) 2019 Consilium Medicum This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |